Epionics SPINE Valid Tool to Measure Spine Mobility in Patients With Axial Spondyloarthritis

spondyloarthritis, axial spondyloarthritis, SpA, axSpA
Credit: Medical Images
Researchers evaluated the role of epionics SPINE in the assessment of spinal mobility in patients with axial spondyloarthritis.

Epionics SPINE (ES) was found to be an objective performance measure and valid tool in assessing spinal mobility in patients with axial spondyloarthritis (axSpA), according to study results published in The Journal of Rheumatology.

The aim of the study was to evaluate the ES device in the assessment of spinal mobility in patients with axSpA.

A total of 153 individuals (114 men) were included in the study, 40 of whom had nonradiographic axSpA, 94 had radiographic axSpA, and 19 healthy control participants. Participants were also evaluated using the Bath Ankylosing Spondylitis Metrology Index (BASMI) and Bath Ankylosing Spondylitis Functional Index (BASFI).

There was a significant negative correlation between BASMI scores and all ES scores (-0.76 ≤ r ≤-0.52) and a weak negative correlation between ES scores and BASFI scores (r >-0.39). Comparisons of ES scores between patients with axSpA and healthy control participants were significant (P <.001). The differences between control participants and patients using ES scores were confirmed in comparisons using covariable adjustments for sex, age, and body mass index. The ES variables of range of motion flexion, extension, rotation, and lateral lumbar flexion were significantly different for patients with nonradiographic and radiographic axSpA.

Study limitations included missing data in several ES variables and lack of assessments for the presence and extent of structural changes in the spine.

Researchers concluded, “Once validated in the field of axSpA, the ES may also be helpful in daily routine, as individual limitations in spinal mobility are directly visualized, thus enabling possible therapy approaches and helping to better understand and assess limitations in functional mobility and exact impairments of patients with axSpA.”

Disclosure: This research was supported by AbbVie. Some authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.


Kiefer D, Baraliakos X, Adolf D, et al. Successful evaluation of spinal mobility measurements with the Epionics SPINE Device in patients with axial spondyloarthritis compared to controls. J Rheumatol. Published online August 15, 202. doi:10.3899/jrheum.201470